Comparative Pharmacology
Head-to-head clinical analysis: CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER versus CEFZIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER versus CEFZIL.
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER vs CEFZIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP 3, leading to cell lysis and death. It has activity against both gram-positive and gram-negative bacteria.
Cefprozil inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking.
1-2 g intravenously every 8-12 hours; typical dose 1 g IV q12h for most infections, 2 g IV q8h for severe infections.
500 mg orally twice daily for 10 days; for uncomplicated skin infections, 250 mg twice daily or 500 mg once daily.
None Documented
None Documented
Approximately 2 hours in adults with normal renal function; prolonged to 4–8 hours in mild-to-moderate renal impairment and up to 13–30 hours in severe impairment (CrCl <30 mL/min).
1.2-1.5 hours in healthy adults; prolonged in renal impairment (e.g., up to 6-8 hours in severe renal failure)
Primarily renal (≥85% unchanged in urine via glomerular filtration and tubular secretion); biliary/fecal excretion minimal (<1%).
Renal: 80-91% unchanged in urine; biliary/fecal: minimal (<5%)
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic